泓博医药：公司将以开放的合作态度，持续强化研发体系的先进性与竞争力

Core Viewpoint - Hongbo Pharmaceutical (301230) is committed to dynamically optimizing its selection of intelligent tool partners based on the evolving needs of its self-developed DiOrion platform and the balance of technical adaptability and cost-effectiveness [1] Group 1 - The company plans to adopt an open collaboration approach to continuously enhance the advancement and competitiveness of its research and development system [1] - Future developments will be communicated through official announcements [1]